Cytotoxicity and Anti-Hepatitis B Virus Activities of Saikosaponins from Bupleurum Species

Abstract

Saikosaponins, the main active constituents of Bupleurum spp., have been shown to possess immunomodulatory, hepatoprotective, anti-tumor and anti-viral activities. In this study, saikosaponins a, c and d were evaluated for cytotoxicity and anti-hepatitis B virus (HBV) activities. Results showed that, with the exception of saikosaponins a and d, HBV-transfected human hepatoma cells (2.2.15 cells) cultured with saikosaponin c showed a significantly lower level of HBeAg in culture medium. Saikosaponin c also possessed activity in inhibiting HBV DNA replication; this inhibitory effect was not due to the cytotoxicity of saikosaponin c or its effect on 2.2.15 cell proliferation. Although saikosaponin d exhibited cytotoxicity on 2.2.15 cells, it failed to inhibit HBV multiplication. The cytotoxicity of saikosaponin d against HepG2 human hepatocellular carcinoma cells was due to the induction of apoptosis through the activation of caspases 3 and 7, which subsequently resulted in poly-ADP-ribose-polymerase (PARP) cleavage. DNA fragmentation was clearly noted at more than 6 h after HepG2 cells exposure to saikosaponin d. The present study concludes that saikosaponin c exhibits anti-HBV activity and saikosaponin d possesses potent cytotoxicity against human hepatocellular carcinoma cells.

Saikosaponins - HBV - Hepatoma - Apoptosis - Hep G2 2.2.15 cells - Bupleurum spec. - Umbelliferae

References

• 1 Yen M H, Lin C C, Chuang C H, Liu S Y. Evaluation of root quality of Bupleurum species by TLC scanner and the liver protective effects of ”Xiao-Chai-Hu-Tang” prepared using three different Bupleurum species.  J Ethnopharmacol. 1991;  34 155-65
• 2 Chang R S, Yeung H W. Inhibition of growth of human immunodeficiency virus in vitro by crude extracts of Chinese medicinal herbs.  Antiviral Res. 1988;  9 163-75
• 3 Ono K, Nakane H, Fukushima M, Chermann J C, Barre-Sinoussi F. Differential inhibition of the activities of reverse transcriptase and various cellular DNA polymerases by a traditional Kampo drug, sho-saiko-to.  Biomed Pharmacother. 1990;  44 13-6
• 4 Gato W, Kadota S, Namba T, Kurokawa M, Shiraki K. Suppression of hepatitis B virus surface antigen secretion by traditional plant medicines.  Phytother Res. 1996;  10 504-7
• 5 Ushio Y, Abe H. The effects of saikosaponin on macrophage functions and lymphocyte proliferation.  Planta Med. 1991;  57 511-4
• 6 Hsu M J, Cheng J S, Huang H C. Effect of saikosaponin, a triterpene saponin, on apoptosis in lymphocytes: association with c-myc, p53, and bcl-2 mRNA.  Br J Pharmacol. 2000;  131 1285-93
• 7 Ushio Y, Abe H. Inactivation of measles virus and herpes simplex virus by saikosaponin d.  Planta Med. 1992;  58 171-3
• 8 Beasley R P, Hwang L Y, Lin C C, Chien C S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.  Lancet. 1981;  2 1129-33
• 9 Beasley R P, Hwang L Y, Lee G C, Lan C C, Roan C H, Huang F Y. et al . Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.  Lancet. 1983;  2 1099-102
• 10 Chang M H, Shau W Y, Chen C J, Wu T C, Kong M S, Liang D C. et al . Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls.  JAMA. 2000;  284 3040-2
• 11 Hope R L, Weltman M, Dingley J, Fiatarone J, Hope A H, Craig P I. et al . Interferon alpha for chronic active hepatitis B. Long-term follow-up of 62 patients: outcomes and predictors of response.  Med J Aust. 1995;  162 8-11
• 12 Niederau C, Heintges T, Lange S, Goldmann G, Niederau C M, Mohr L. et al . Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med. 1996;  334 1422-7
• 13 Soudeyns H, Yao X I, Gao Q, Belleau B, Kraus J L, Nguyen-Ba N. et al . Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.  Antimicrob Agents Chemother. 1991;  35 1386-90
• 14 Doong S L, Tsai C H, Schinazi R F, Liotta D C, Cheng Y C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues.  Proc Natl Acad Sci (USA). 1991;  88 8495-9
• 15 Honkoop P, de Man R A, Heijtink R A, Schalm S W. Hepatitis B reactivation after lamivudine.  Lancet. 1995;  346 1156-7
• 16 Honkoop P, Niesters H G, de Man R A, Osterhaus A D, Schalm S W. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns.  J Hepatol. 1997;  26 1393-5
• 17 David L, Spector R DG, Leslie A. Leinwand Cell - A Laboratory Manual. CSHL Press 1998: pp. 1511
• 18 Ayoola E A, Balayab M S, Deinhardt F, Gust I, Kureshi A W, Maynard J E. et al . Bull.  World Health Org. 1988;  66 443-55
• 19 Beasley R P, Hwang L Y, Lin C C, Leu M L, Stevens C E, Szmuness W, Chen K P. Incidence of hepatitis B virus infections in preschool children in Taiwan.  J Infect Dis. 1982;  146 198-204
• 20 Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B.  Hepatol. 1988;  8 1651-4
• 21 Tipples G A, Ma M M, Fischer K P, Bain V G, Kneteman N M, Tyrrell D L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo .  Hepatol. 1996;  24 714-7